BioSpace News Archive

While approved in non-small cell lung cancer, Keytruda failed to provide benefit for the TKI-resistant, EGFR-mutant subtype of the disease.

Neurologist David Weisman, with financial ties to the companies, was removed from the FDA’s upcoming advisory committee meeting slated to consider Leqembi’s traditional approval.

Biogen, and partner Denali, are discontinuing the Phase III LIGHTHOUSE study of BIIB122 in Parkinson’s disease due to the trial’s long timeline and complexity.

In a lawsuit filed Tuesday in federal district court, Merck claimed that the price negotiation program laid out in the Inflation Reduction Act violates the U.S. Constitution.

A Kenilworth, NJ, R&D campus that formerly served as Merck’s global headquarters is now set to reopen and become the Northeast Science and Technology (NEST) Center.

Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle delivery systems for molecular therapeutics.

Ceek Women’s Health, an award-winning medical device company, is proud to introduce the Nella Single-Use Vaginal Speculum with Integrated Sidewall Retractors and LED Light.

Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to five new employees with a grant date of June 1, 2023, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

Rhythm Pharmaceuticals, Inc. announced that on June 2, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 33,450 shares of its common stock to seven new employees, consisting of inducement stock options to purchase an aggregate of 22,300 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 11,150 shares of its common stock.

Gradalis Inc. announced the peer-reviewed publication in Advanced NanoBioMed, highlighting the therapeutic applications of a new extracellular matrix platform developed for tumor cell expansion in collaboration with the University of Michigan Biointerfaces Institute.